RGTLF (Argent Biopharma) OCF Margin %: -1,519.30% (As of Dec. 2025)


What is Argent Biopharma OCF Margin %?

Argent Biopharma RGTLF OCF Margin % is -1,519.30% as of Dec. 2025. The stock has 8 warning signs investors should review. Among 959 Drug Manufacturers companies, Argent Biopharma ranks worse than 97.39% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Argent Biopharma's Cash Flow from Operations for the six months ended in Dec. 2025 was $-1.73 Mil. Argent Biopharma's Revenue for the six months ended in Dec. 2025 was $0.11 Mil. Therefore, Argent Biopharma's OCF Margin % for the quarter that ended in Dec. 2025 was -1,519.30%.

As of today, Argent Biopharma's current OCF Yield % is -180.27%.

The historical rank and industry rank for Argent Biopharma's OCF Margin % or its related term are showing as below:

RGTLF' s OCF Margin % Range Over the Past 10 Years
Min: -3880   Med: -968.6   Max: -228.87
Current: -1890.15

During the past 13 years, the highest OCF Margin % of Argent Biopharma was -228.87%. The lowest was -3880.00%. And the median was -968.60%.

RGTLF's OCF Margin % is ranked worse than
97.39% of 959 companies
in the Drug Manufacturers industry
Industry Median: 9.95 vs RGTLF: -1890.15

Argent Biopharma OCF Margin % Related Terms

Argent Biopharma OCF Margin % Historical Data

* Premium members only.

The historical data trend for Argent Biopharma's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argent Biopharma OCF Margin % Chart

Argent Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -419.69 -228.90 -310.51 -1,599.66 -1,590.00

Argent Biopharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -838.67 12,057.14 -1,208.48 -2,172.00 -1,519.30

RGTLF vs ZTS, UTHR: OCF Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Argent Biopharma OCF Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Argent Biopharma's OCF Margin % falls into.


Argent Biopharma OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Argent Biopharma's OCF Margin for the fiscal year that ended in Jun. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-6.042/0.38
=-1,590.00 %

Argent Biopharma's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-1.732/0.114
=-1,519.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -1,519.30% mean?
Argent Biopharma (RGTLF) has a OCF Margin % of -1,519.30% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Argent Biopharma and its competitors. According to the industry distribution chart, Argent Biopharma ranks #934 out of 959 companies in the Drug Manufacturers industry, placing it in the top 97.4%.
Is Argent Biopharma's OCF Margin % too high?
Argent Biopharma's current OCF Margin % is -1,519.30%. Based on the distribution chart, Argent Biopharma ranks #934 out of 959 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Argent Biopharma's OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Argent Biopharma ranks #934 out of 959 companies for OCF Margin %. This places Argent Biopharma in the lower half of its industry. The industry median OCF Margin % is 9.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Argent Biopharma and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Argent Biopharma's current OCF Margin % is -1,519.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argent Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Argent Biopharma (RGTLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 25% above its estimated fair value. The current OCF Margin % is -1,519.30%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Argent Biopharma (RGTLF), the current OCF Margin % is -1,519.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Argent Biopharma Business Description

Other Exchanges H5O0:GermanyRGT:Australia
Address 295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.